BeiGene, Ltd. (BGNE) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is John V. Oyler.
BGNE has IPO date of 2016-02-03, 10,600 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $20.21B.
BeiGene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for cancer treatment globally. The company's commercial portfolio includes approved drugs such as BRUKINSA for mantle cell lymphoma, Tislelizumab for Hodgkin's lymphoma, and several other therapies for hematologic and solid tumors, complemented by a robust pipeline of clinical-stage candidates targeting various cancer types through innovative mechanisms including BTK inhibitors, PD-1/PD-L1 antibodies, kinase inhibitors, and specialized immunotherapies. BeiGene maintains strategic partnerships with leading pharmaceutical companies including Amgen, Novartis, and Bristol Myers Squibb to strengthen its research and commercialization capabilities. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company operates a comprehensive oncology platform serving patients worldwide.
